Research-use kit interrogates 84 genes using single-tube protocol, compatible with existing molecular laboratory equipment.
Pillar Biosciences has launched oncoReveal Lymphoid, a research-use-only next-generation sequencing (NGS) kit designed for rapid tumor profiling of lymphoid malignancies in molecular laboratories.
The NGS panel interrogates 84 genes of interest, including full coding DNA sequence of 29 genes, using a single-tube, fully automated workflow that can be performed by any NGS-equipped molecular laboratory, according to the Natick, Massachusetts-based company.
“We are excited to launch oncoReveal Lymphoid, specifically designed to meet the needs of local laboratories looking for rapid and efficient NGS-based testing solutions to help interrogate lymphomas,” says ShiPing Zou, senior director of product management at Pillar Biosciences, in a release. “oncoReveal Lymphoid is compatible with our current heme-oncology offerings including oncoReveal Myeloid and oncoReveal Heme Fusion.”
Proprietary Technology Platform
The panel uses Pillar’s proprietary stem-loop inhibition-mediated amplification technology, a tiled amplicon-based library preparation chemistry designed to provide genetic profiles down to 2% variant allele frequency. The system is powered by PiVAT, an automated secondary bioinformatics software that supports identification of somatic mutations from DNA with high sensitivity and specificity.
Pillar’s PiVAT technology is fully compatible with third-party clinical reporting solutions, according to the company.
Expanding Hematology-Oncology Coverage
The new lymphoid panel joins Pillar’s existing hematology-oncology portfolio to provide coverage of heme oncology tumor profiling needs for molecular pathology laboratories. Together with oncoReveal Myeloid and oncoReveal Heme Fusion, the suite addresses various blood cancer testing requirements.
According to Blood Cancer United, approximately 186,400 people in the US will be diagnosed with blood cancer in 2024, representing about 10% of all new cancer cases.
Pillar Biosciences specializes in decision medicine, which utilizes NGS testing technology for tumor profiling, therapy selection, and recurrence monitoring in cancer patients. The company offers more than 20 NGS testing kits in IVD or research-use formats, with multiple panels in development.
ID 128276917 © Katerynakon | Dreamstime.com
